Oncology: Educational Materials

These are online medical education resources. The educational material(s) are intended for healthcare providers practicing in the United States.


Identifying Patients with HR+ HER2- Early Breast Cancer who are at a Higher Risk of Recurrence

~20% of patients with HR+/HER2- EBC may progress to metastatic disease, commonly within a few years after primary treatment. This slide deck provides details on the clinical & pathological factors that may affect the risk of recurrence in people with EBC.

Date of Last Review: December 01, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Visit Us @LillyMedical